$282.55
Value $681B
JNJ and LAB stock compared: price, dividend, valuation and results, from SEC filings.
$282.55
Value $681B
$0.62
Value $242M
Johnson & Johnson (JNJ) has a market value of $681B and Standard BioTools (LAB) $242M. Over the last year, with dividends, JNJ moved +47.5% and LAB -49.9%. Dividend yield: JNJ 1.87%, LAB none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
JNJ$681B
LAB$242M
JNJ is 2,811 times LAB
Revenue, 12 months
JNJ$99.3B
LAB$84M
JNJ is 1,177 times LAB
Net income, 12 months
JNJ$16.1B
LAB$133M
JNJ is 121 times LAB
Operating margin
JNJ–
LAB-97.5%
ROIC
JNJ12.4%
LAB-13.1%
25.5 points apart
P/E
JNJ42.3
LAB–
Dividend yield
JNJ1.9%
LAB0.0%
1.9 points apart
5-year return
JNJ+98.6%
LAB-87.0%
185.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
JNJ+98.6%
LAB-86.9%
| Period | JNJWith dividends | LABWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +47.5%Price +44.2% | -49.9%Price -49.9% |
| 3 years since November 16, 2023 | +105.0%+27.0% a yearPrice +88.2% | -71.8%-34.4% a yearPrice -71.8% |
| 5 years since November 15, 2021 | +98.6%+14.7% a yearPrice +72.8% | -87.0%-33.5% a yearPrice -87.0% |
| 10 years since November 16, 2016 | +218.6%+12.3% a yearPrice +142.8% | -89.7%-20.3% a yearPrice -89.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
JNJJohnson & JohnsonLABStandard BioTools
| Price | $282.55 | $0.62 |
|---|---|---|
| Market value | $681B | $242M |
| Enterprise value (EV) | $708B | – |
| P/E | 42.3 | – |
| P/E, 5-year median | 21.9 | – |
| P/B | 8.4 | 0.4 |
| EV/EBIT | 39.9 | – |
| Free cash flow yield | 3.0% | – |
| Revenue, 12 months | $99.3B | $84M |
|---|---|---|
| Net income, 12 months | $16.1B | $133M |
| Free cash flow, 12 months | $20.6B | -$66M |
| Earnings per share, 12 months | $6.59 | $0.34 |
| Revenue growth, year on year | 6.1% | -6.2% |
| Revenue growth a year, past | +2.7%over 5 years | -9.2%over 5 years |
| EPS growth a year, past | +14.9%over 5 years | – |
| Gross margin | 67.6% | 52.2% |
|---|---|---|
| Operating margin | – | -97.5% |
| Net margin | 16.2% | 157.6% |
| ROIC | 12.4% | -13.1% |
| ROE | 19.7% | 26.8% |
| Cash | $17.2B | $461M |
|---|---|---|
| Total debt | $44.7B | $27M |
| Net debt / EBITDA | 1.1 | – |
| Interest cover | 18.0× | – |
| Dividend yield | 1.9% | – |
|---|---|---|
| Dividend per share, 12 months | $5.28 | – |
| Dividend growth a year, past | +5.3%over 5 years | – |
| Buyback yield | 0.9% | – |
| Shareholder yield | 2.7% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($681B) is about 2,811.0 times Standard BioTools ($242M), at today's prices.
Since November 16, 2016, JNJ's price moved +142.8% and LAB's -89.7%. With dividends: JNJ +218.6% (+12.3% a year), LAB -89.7% (-20.3% a year). Past returns do not predict future ones.
The dividend yield at today's price is 1.87% for Johnson & Johnson and none for Standard BioTools. Over the last twelve months they paid $5.28 and – per share.
Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 157.6% for Standard BioTools, and the operating margin – and -97.5%. Revenue was $99.3B and $84M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.